Several countries have introduced more stringent testing requirements such as nucleic acid testing (NAT) for hepatitis B (HBV), hepatitis C (HCV) and/or human immunodeficiency virus (HIV) for non-reproductive and/or reproductive tissue and cells, whereas in most Member States and EEA countries the use of this type of testing is not required on the basis of a cost-benefit analysis and/or the epidemiological context.
Diversi pajjiżi introduċew rekwiżiti aktar stretti għall-ittestjar bħall-ittestjar tal-aċidu nuklejku (NAT) għall-epatite B (HBV), epatite Ċ (HCV) u/jew virus tal-immunodefiċjenza umana (HIV) għal tessuti u ċelloli mhux riproduttivi u/jew riproduttivi, mentri f'ħafna mill-Istati Membri u pajjiżi taż-ŻEE l-użu ta' dan it-tip ta' ttestjar mhuwiex meħtieġ abbażi tal-analiżi tal-ispiża u l-benefiċċju u/jew il-kuntest epidemjoloġiku.